{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T05:06:28Z","timestamp":1779253588925,"version":"3.51.4"},"reference-count":27,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infectious Disease Reports"],"abstract":"<jats:p>Background: Anti-MRSA agents are essential for treating severe infections, yet their use is constrained by distinct toxicity profiles. However, comparative real-world data remain scarce. Methods: This nationwide pharmacovigilance study used the Japanese Adverse Drug Event Report (JADER) database (2004\u20132025). Disproportionality analyses (proportional reporting ratio [PRR]) were performed at the Standardized MedDRA Query and Preferred Term levels, complemented by Weibull-based time-to-onset modeling, to characterize AE patterns associated with vancomycin (VCM), teicoplanin (TEIC), arbekacin (ABK), daptomycin (DAP), linezolid (LZD), and tedizolid (TZD). Results: Distinct agent-specific AE profiles were observed. VCM showed disproportionate reporting of acute renal failure (PRR 6.66) and severe cutaneous reactions. TEIC displayed fewer renal signals but relatively higher reporting of hematologic events (PRR 3.51). ABK demonstrated high disproportionality in acute and chronic renal failure, reflecting aminoglycoside nephrotoxicity. DAP showed a high reporting signal for eosinophilic pneumonia (PRR 23.30), interstitial lung disease, and creatine kinase elevation\/rhabdomyolysis, with wear-out hazard patterns suggesting a possible time-dependent reporting tendency. LZD exhibited hematopoietic signals (PRR 6.13) and additional associations with hyponatremia, lactic acidosis, and optic neuropathy, consistent with marrow suppression and mitochondrial toxicity. Weibull analysis indicated cumulative \u201cwear-out\u201d risks for renal, hepatic, and hematologic events, whereas hypersensitivity and many pulmonary events followed random-failure patterns. Conclusions: This large-scale JADER analysis delineated the distinct safety profiles of the six anti-MRSA agents. The key findings included DAP pulmonary and muscle toxicities, LZD hematological events, and VCM nephrotoxicity. Time-to-onset modeling indicates potential cumulative versus random risk patterns, suggesting the need for individualized monitoring and cross-validation.<\/jats:p>","DOI":"10.3390\/idr18030043","type":"journal-article","created":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T01:12:09Z","timestamp":1777857129000},"page":"43","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Real-World Pharmacovigilance Analysis of the Safety Profiles Associated with Anti-MRSA Agents Using the Japanese Adverse Drug Event Report (JADER) Database"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4606-7150","authenticated-orcid":false,"given":"Yuki","family":"Hanai","sequence":"first","affiliation":[{"name":"Laboratory of Clinical Infectious Diseases and Therapeutics, Meiji Pharmaceutical University, Tokyo 204-8588, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0993-6019","authenticated-orcid":false,"given":"Shusuke","family":"Uekusa","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, Chiba 274-8510, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizuki","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, Chiba 274-8510, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kohei","family":"Shimoyama","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Toho University Omori Medical Center, Tokyo 143-8541, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayato","family":"Ohashi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Toho University Omori Medical Center, Tokyo 143-8541, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Nishimura","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Toho University Omori Medical Center, Tokyo 143-8541, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sachiko","family":"Yanagino","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Toho University Omori Medical Center, Tokyo 143-8541, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4804-9708","authenticated-orcid":false,"given":"Takahiro","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Toho University Omori Medical Center, Tokyo 143-8541, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6154-5091","authenticated-orcid":false,"given":"Kazuhiro","family":"Matsuo","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Toho University, Chiba 274-8510, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1128\/CMR.00081-09","article-title":"Community-associated methicillin-resistant Staphylococcus aureus: Epidemiology and clinical consequences of an emerging epidemic","volume":"23","author":"David","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jiac.2015.02.008","article-title":"Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2010: General view of the pathogens\u2019 antibacterial susceptibility","volume":"21","author":"Yanagihara","year":"2015","journal-title":"J. Infect. Chemother."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1002\/cpt.726","article-title":"The nephrotoxicity of vancomycin","volume":"102","author":"Filippone","year":"2017","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ajhp\/zxaa036","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: A revised consensus guideline and review by the American Society of Health System Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"77","author":"Rybak","year":"2020","journal-title":"Am. J. Health Syst. Pharm."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"4069","DOI":"10.1128\/AAC.00341-09","article-title":"Comparative efficacy and safety of vancomycin versus teicoplanin: Systematic review and meta-analysis","volume":"53","author":"Svetitsky","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1128\/AAC.00480-05","article-title":"Pharmacokinetic-pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus","volume":"50","author":"Sato","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Rivetti, S., Romano, A., Mastrangelo, S., Attin\u00e0, G., Maurizi, P., and Ruggiero, A. (2023). Aminoglycosides-related ototoxicity: Mechanisms, risk factors, and prevention in pediatric patients. Pharmaceuticals, 16.","DOI":"10.3390\/ph16101353"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1086\/652767","article-title":"Daptomycin exposure and the probability of elevations in the creatine phosphokinase level: Data from a randomized trial of patients with bacteremia and endocarditis","volume":"50","author":"Bhavnani","year":"2010","journal-title":"Clin. Infect. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1086\/345744","article-title":"Linezolid for the treatment of multidrug-resistant, gram-positive infections: Experience from a compassionate-use program","volume":"36","author":"Birmingham","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.jiac.2016.05.003","article-title":"A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemia","volume":"22","author":"Hanai","year":"2016","journal-title":"J. Infect. Chemother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.21873\/invivo.13382","article-title":"Association of torsade de pointes and QT prolongation with antifungal triazoles: Analysis using a pharmacovigilance database","volume":"37","author":"Ohyama","year":"2023","journal-title":"In Vivo"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"25943","DOI":"10.1038\/s41598-024-77052-y","article-title":"Evaluation of tolvaptan-associated hepatic disorder using different national pharmacovigilance databases","volume":"14","author":"Uno","year":"2024","journal-title":"Sci. Rep."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1159\/000531390","article-title":"Adverse event profile of azacitidine: Analysis by route of administration using Japanese pharmacovigilance database","volume":"101","author":"Yamaoka","year":"2023","journal-title":"Oncology"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"Bate","year":"2002","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"ofad414","DOI":"10.1093\/ofid\/ofad414","article-title":"Pharmacovigilance study on eosinophilic pneumonia induced by anti-MRSA agents: Analysis based on the FDA Adverse Event Reporting System","volume":"10","author":"Okada","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13756-016-0158-8","article-title":"Daptomycin-induced eosinophilic pneumonia\u2014A systematic review","volume":"5","author":"Uppal","year":"2016","journal-title":"Antimicrob. Resist. Infect. Control."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1007\/s15010-024-02349-z","article-title":"Daptomycin eosinophilic pneumonia, a systematic review of the literature and case series","volume":"52","author":"Gidari","year":"2024","journal-title":"Infection"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1016\/j.clinthera.2009.10.017","article-title":"Retrospective cohort chart review study of factors associated with the development of thrombocytopenia in adult Japanese patients who received intravenous linezolid therapy","volume":"31","author":"Niwa","year":"2009","journal-title":"Clin. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1080\/14740338.2024.2309225","article-title":"Hematological adverse events associated with anti-MRSA agents: A real-world analysis based on FAERS","volume":"23","author":"Yu","year":"2024","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_22","first-page":"61","article-title":"Optic neuropathy associated with linezolid: Systematic review of cases","volume":"43","year":"2019","journal-title":"Farm. Hosp."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.mito.2011.08.010","article-title":"Rapid-onset, linezolid-induced lactic acidosis in MELAS","volume":"11","author":"Cope","year":"2011","journal-title":"Mitochondrion"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1111\/bcp.15429","article-title":"Risk factors for vancomycin-associated acute kidney injury: A systematic review and meta-analysis","volume":"88","author":"Kim","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/FTD.0000000000001075","article-title":"Area-under-curve-guided versus trough-guided monitoring of vancomycin and its impact on nephrotoxicity: A systematic review and meta-analysis","volume":"45","author":"Lim","year":"2023","journal-title":"Ther. Drug Monit."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0924-8579(98)00025-9","article-title":"Comparative safety of teicoplanin and vancomycin","volume":"10","author":"Wilson","year":"1998","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1080\/14740338.2024.2442023","article-title":"Vancomycin and linezolid: Severe cutaneous adverse reactions to drugs","volume":"25","author":"Li","year":"2024","journal-title":"Expert. Opin. Drug Saf."}],"container-title":["Infectious Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2036-7449\/18\/3\/43\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T04:12:21Z","timestamp":1779250341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2036-7449\/18\/3\/43"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,2]]},"references-count":27,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["idr18030043"],"URL":"https:\/\/doi.org\/10.3390\/idr18030043","relation":{},"ISSN":["2036-7449"],"issn-type":[{"value":"2036-7449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,2]]}}}